From the Food and Drug Administration.
Nightingale
S L
SL
Office of Health Affairs, FDA, Rockville, MD 20857.
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D001241:Aspirin / Q000009:adverse effects*; D001500:BCG Vaccine; D002278:Carcinoma in Situ / Q000628:therapy*; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000628:therapy*; D003131:Combined Modality Therapy; D004348:Drug Labeling; D015507:Drugs, Investigational / Q000627:therapeutic use; D006801:Humans; D011050:Policy Making; D014481:United States; D014486:United States Food and Drug Administration; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D001500:BCG Vaccine; D015507:Drugs, Investigational; D001241:Aspirin